Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of ZIOPHARM Oncology Inc (NASDAQ: ZIOP) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of ZIOPHARM Oncology Inc (NASDAQ: ZIOP)  concerning whether a series of statements by ZIOPHARM Oncology Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On July 14, 2016, Ziopharm disclosed that a brain cancer patient in an ongoing clinical trial had died after being treated with the Company's experimental gene therapy, Ad-RTS-hIL-12.  According to a Company spokesman, Ziopharm had not yet informed the U.S. Food and Drug Administration of the death. Ziopharm also revealed the death of a second patient in the Ziopharm gene therapy study, for reasons that the Company described as unrelated to Ad-RTS-hIL-12.  Ziopharm was trying to raise $50 million in a stock offering that week but the deal was abandoned on the night of July 14, 2016 according to an email sent by Jefferies & Co. bankers.

Following this news, NASDAQ: ZIOP has fallen as much as $1.11, or 19.58%, to $4.56 during intraday trading on July 15, 2016.

Based in Boston, Massachusetts, ZIOPHARM Oncology Inc focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology.

If you purchased shares of ZIOPHARM Oncology Inc (NASDAQ: ZIOP) on or before July 14, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185